Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/ neu extracellular domain plus anti-HER2/ neu IgG3-(IL-2) or anti-HER2/ neu IgG3-(GM-CSF) fusion protein
In the present study, we demonstrate that a physical association between the extracellular domain of human HER2/ neu receptor (ECD HER2) plus anti-HER2/ neu IgG3-(IL-2) or anti-HER2/ neu IgG3-(GM-CSF) was required to elicit the most effective anti-tumor immune response against a syngeneic tumor expr...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2005-09, Vol.23 (39), p.4793-4803 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4803 |
|---|---|
| container_issue | 39 |
| container_start_page | 4793 |
| container_title | Vaccine |
| container_volume | 23 |
| creator | Dela Cruz, Jay S. Morrison, Sherie L. Penichet, Manuel L. |
| description | In the present study, we demonstrate that a physical association between the extracellular domain of human HER2/
neu receptor (ECD
HER2) plus anti-HER2/
neu IgG3-(IL-2) or anti-HER2/
neu IgG3-(GM-CSF) was required to elicit the most effective anti-tumor immune response against a syngeneic tumor expressing rat HER2/
neu. Immune effectors including CD4
+, CD8
+, and NK cells contributed to protection against tumor growth. Vaccinated B-cell deficient mice did not elicit tumor protection, suggesting a critical role for B-cells in a protective immune response. These results provide insights into the mechanisms responsible for the protective tumor immunity elicited when antibody-(IL-2 or GM-CSF) are used as enhancers of vaccines targeting tumor antigens. |
| doi_str_mv | 10.1016/j.vaccine.2005.04.041 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68513068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X05005128</els_id><sourcerecordid>68513068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-d5296fe30186ec47730e67d8fb2ba505dfb336688b9e475376258f6fad2119083</originalsourceid><addsrcrecordid>eNqFkV2L1DAYhYso7rj6E5TcKO5FZ_PRpO2VyLA7OzAi-AHehTR9u83QpGuSru7f85eZsYW5ERZeyEWec86bnCx7TfCaYCIuD-t7pbVxsKYY8zUu0pAn2YpUJcspJ9XTbIWpKPKC4B9n2YsQDjiBjNTPszPCa1Hyolhlf3YumNs-BmRcHFHsAVnQvXImWDR2SLlo8jjZ0SNj7eRMfEgkskYDmhdQEVr0y8T-n7ifrHLo5uoLvUQOJgS_o1cahmEalEftaFVS3w1TmJ1P4O52y_L3u31OL1AK--_t9lO--Xp9gbopmDHZ-DGCcS-zZ50aArxazvPs-_XVt81Nvv-83W0-7nNd0CLmLae16IBhUgnQRVkyDKJsq66hjeKYt13DmBBV1dRQlJyVgvKqE51qKSE1rth59m72Tbk_JwhRWhOOT1MOxilIUXHCsHgcJGXyrwVLIJ9B7ccQPHTyzhur_IMkWB5blge5tCyPLUtcpCFJ92YJmBoL7Um11JqAtwugglZD55XTJpy4EnNeY5q4DzMH6d_uDXgZtAGnoTUedJTtaB5Z5S8dAsZo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17475963</pqid></control><display><type>article</type><title>Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/ neu extracellular domain plus anti-HER2/ neu IgG3-(IL-2) or anti-HER2/ neu IgG3-(GM-CSF) fusion protein</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><creator>Dela Cruz, Jay S. ; Morrison, Sherie L. ; Penichet, Manuel L.</creator><creatorcontrib>Dela Cruz, Jay S. ; Morrison, Sherie L. ; Penichet, Manuel L.</creatorcontrib><description>In the present study, we demonstrate that a physical association between the extracellular domain of human HER2/
neu receptor (ECD
HER2) plus anti-HER2/
neu IgG3-(IL-2) or anti-HER2/
neu IgG3-(GM-CSF) was required to elicit the most effective anti-tumor immune response against a syngeneic tumor expressing rat HER2/
neu. Immune effectors including CD4
+, CD8
+, and NK cells contributed to protection against tumor growth. Vaccinated B-cell deficient mice did not elicit tumor protection, suggesting a critical role for B-cells in a protective immune response. These results provide insights into the mechanisms responsible for the protective tumor immunity elicited when antibody-(IL-2 or GM-CSF) are used as enhancers of vaccines targeting tumor antigens.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2005.04.041</identifier><identifier>PMID: 15967544</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Antibody ; Applied microbiology ; B-Lymphocytes - immunology ; Biological and medical sciences ; Cancer Vaccines - immunology ; CD4-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - immunology ; Cytokine ; Female ; Fundamental and applied biological sciences. Psychology ; Granulocyte-Macrophage Colony-Stimulating Factor - immunology ; Humans ; Immunoglobulin G - immunology ; Killer Cells, Natural - immunology ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Microbiology ; Receptor, ErbB-2 - immunology ; Recombinant Fusion Proteins - immunology ; Tumors ; Vaccination ; Vaccine ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Synthetic - immunology</subject><ispartof>Vaccine, 2005-09, Vol.23 (39), p.4793-4803</ispartof><rights>2005 Elsevier Ltd</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-d5296fe30186ec47730e67d8fb2ba505dfb336688b9e475376258f6fad2119083</citedby><cites>FETCH-LOGICAL-c424t-d5296fe30186ec47730e67d8fb2ba505dfb336688b9e475376258f6fad2119083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.vaccine.2005.04.041$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978,64368</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17055902$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15967544$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dela Cruz, Jay S.</creatorcontrib><creatorcontrib>Morrison, Sherie L.</creatorcontrib><creatorcontrib>Penichet, Manuel L.</creatorcontrib><title>Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/ neu extracellular domain plus anti-HER2/ neu IgG3-(IL-2) or anti-HER2/ neu IgG3-(GM-CSF) fusion protein</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>In the present study, we demonstrate that a physical association between the extracellular domain of human HER2/
neu receptor (ECD
HER2) plus anti-HER2/
neu IgG3-(IL-2) or anti-HER2/
neu IgG3-(GM-CSF) was required to elicit the most effective anti-tumor immune response against a syngeneic tumor expressing rat HER2/
neu. Immune effectors including CD4
+, CD8
+, and NK cells contributed to protection against tumor growth. Vaccinated B-cell deficient mice did not elicit tumor protection, suggesting a critical role for B-cells in a protective immune response. These results provide insights into the mechanisms responsible for the protective tumor immunity elicited when antibody-(IL-2 or GM-CSF) are used as enhancers of vaccines targeting tumor antigens.</description><subject>Animals</subject><subject>Antibody</subject><subject>Applied microbiology</subject><subject>B-Lymphocytes - immunology</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - immunology</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cytokine</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - immunology</subject><subject>Humans</subject><subject>Immunoglobulin G - immunology</subject><subject>Killer Cells, Natural - immunology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Microbiology</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>Recombinant Fusion Proteins - immunology</subject><subject>Tumors</subject><subject>Vaccination</subject><subject>Vaccine</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Synthetic - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV2L1DAYhYso7rj6E5TcKO5FZ_PRpO2VyLA7OzAi-AHehTR9u83QpGuSru7f85eZsYW5ERZeyEWec86bnCx7TfCaYCIuD-t7pbVxsKYY8zUu0pAn2YpUJcspJ9XTbIWpKPKC4B9n2YsQDjiBjNTPszPCa1Hyolhlf3YumNs-BmRcHFHsAVnQvXImWDR2SLlo8jjZ0SNj7eRMfEgkskYDmhdQEVr0y8T-n7ifrHLo5uoLvUQOJgS_o1cahmEalEftaFVS3w1TmJ1P4O52y_L3u31OL1AK--_t9lO--Xp9gbopmDHZ-DGCcS-zZ50aArxazvPs-_XVt81Nvv-83W0-7nNd0CLmLae16IBhUgnQRVkyDKJsq66hjeKYt13DmBBV1dRQlJyVgvKqE51qKSE1rth59m72Tbk_JwhRWhOOT1MOxilIUXHCsHgcJGXyrwVLIJ9B7ccQPHTyzhur_IMkWB5blge5tCyPLUtcpCFJ92YJmBoL7Um11JqAtwugglZD55XTJpy4EnNeY5q4DzMH6d_uDXgZtAGnoTUedJTtaB5Z5S8dAsZo</recordid><startdate>20050915</startdate><enddate>20050915</enddate><creator>Dela Cruz, Jay S.</creator><creator>Morrison, Sherie L.</creator><creator>Penichet, Manuel L.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20050915</creationdate><title>Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/ neu extracellular domain plus anti-HER2/ neu IgG3-(IL-2) or anti-HER2/ neu IgG3-(GM-CSF) fusion protein</title><author>Dela Cruz, Jay S. ; Morrison, Sherie L. ; Penichet, Manuel L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-d5296fe30186ec47730e67d8fb2ba505dfb336688b9e475376258f6fad2119083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Antibody</topic><topic>Applied microbiology</topic><topic>B-Lymphocytes - immunology</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - immunology</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cytokine</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - immunology</topic><topic>Humans</topic><topic>Immunoglobulin G - immunology</topic><topic>Killer Cells, Natural - immunology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Microbiology</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>Recombinant Fusion Proteins - immunology</topic><topic>Tumors</topic><topic>Vaccination</topic><topic>Vaccine</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Synthetic - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dela Cruz, Jay S.</creatorcontrib><creatorcontrib>Morrison, Sherie L.</creatorcontrib><creatorcontrib>Penichet, Manuel L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dela Cruz, Jay S.</au><au>Morrison, Sherie L.</au><au>Penichet, Manuel L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/ neu extracellular domain plus anti-HER2/ neu IgG3-(IL-2) or anti-HER2/ neu IgG3-(GM-CSF) fusion protein</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2005-09-15</date><risdate>2005</risdate><volume>23</volume><issue>39</issue><spage>4793</spage><epage>4803</epage><pages>4793-4803</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>In the present study, we demonstrate that a physical association between the extracellular domain of human HER2/
neu receptor (ECD
HER2) plus anti-HER2/
neu IgG3-(IL-2) or anti-HER2/
neu IgG3-(GM-CSF) was required to elicit the most effective anti-tumor immune response against a syngeneic tumor expressing rat HER2/
neu. Immune effectors including CD4
+, CD8
+, and NK cells contributed to protection against tumor growth. Vaccinated B-cell deficient mice did not elicit tumor protection, suggesting a critical role for B-cells in a protective immune response. These results provide insights into the mechanisms responsible for the protective tumor immunity elicited when antibody-(IL-2 or GM-CSF) are used as enhancers of vaccines targeting tumor antigens.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15967544</pmid><doi>10.1016/j.vaccine.2005.04.041</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2005-09, Vol.23 (39), p.4793-4803 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68513068 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE; ProQuest Central UK/Ireland |
| subjects | Animals Antibody Applied microbiology B-Lymphocytes - immunology Biological and medical sciences Cancer Vaccines - immunology CD4-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - immunology Cytokine Female Fundamental and applied biological sciences. Psychology Granulocyte-Macrophage Colony-Stimulating Factor - immunology Humans Immunoglobulin G - immunology Killer Cells, Natural - immunology Medical sciences Mice Mice, Inbred BALB C Microbiology Receptor, ErbB-2 - immunology Recombinant Fusion Proteins - immunology Tumors Vaccination Vaccine Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Synthetic - immunology |
| title | Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/ neu extracellular domain plus anti-HER2/ neu IgG3-(IL-2) or anti-HER2/ neu IgG3-(GM-CSF) fusion protein |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T12%3A58%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insights%20into%20the%20mechanism%20of%20anti-tumor%20immunity%20in%20mice%20vaccinated%20with%20the%20human%20HER2/%20neu%20extracellular%20domain%20plus%20anti-HER2/%20neu%20IgG3-(IL-2)%20or%20anti-HER2/%20neu%20IgG3-(GM-CSF)%20fusion%20protein&rft.jtitle=Vaccine&rft.au=Dela%20Cruz,%20Jay%20S.&rft.date=2005-09-15&rft.volume=23&rft.issue=39&rft.spage=4793&rft.epage=4803&rft.pages=4793-4803&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2005.04.041&rft_dat=%3Cproquest_cross%3E68513068%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17475963&rft_id=info:pmid/15967544&rft_els_id=S0264410X05005128&rfr_iscdi=true |